Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: Effects of absorption enhancers

被引:46
作者
Marttin, E
Verhoef, JC
Cullander, C
Romeijn, SG
Nagelkerke, JF
Merkus, FWHM
机构
[1] LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV PHARMACEUT TECHNOL & BIOPHARMACEUT,NL-2300 RA LEIDEN,NETHERLANDS
[2] UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143
[4] LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV TOXICOL,NL-2300 RA LEIDEN,NETHERLANDS
关键词
confocal laser scanning microscopy; nasal drug delivery; in vivo administration; cyclodextrins; sodium taurodihydrofusidate; fluorescent-labelled dextrans;
D O I
10.1023/A:1012109329631
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To visualize the transport pathway(s) of high molecular weight model compounds across rat nasal epithelium in vivo using confocal laser scanning microscopy. Furthermore, the influence of nasal absorption enhancers (randomly methylated beta-cyclodextrin and sodium taurodihydrofusidate) on this transport was studied. Methods. Fluorescein isothiocyanate (FITC)-labelled dextrans with a molecular weight of 3,000 or 10,000 Da were administered intranasally to rats. Fifteen minutes after administration the tissue was fixed with Bouin. The nasal septum was surgically removed and stained with Evans Blue protein stain or DiIC18(5) lipid stain prior to visualization with the confocal laser scanning microscope. Results. Transport of FITC-dextran 3,000 across nasal epithelium occurred via the paracellular pathway. Endocytosis of FITC-dextran 3,000 was also shown. In the presence of randomly methylated beta-cyclodextrin 2% (w/v) similar transport pathways for FITC-dextran 3,000 were observed. With sodium taurodihydrofusidate 1% (w/v) the transport route was also paracellular with endocytosis, but cells were swollen and mucus was extruded into the nasal cavity. For FITC-dextran 10,000 hardly any transport was observed without enhancer, or after co-administration with randomly methylated beta-cyclodextrin 2% (w/v). Co-administration with sodium taurodihydrofusidate 1% (w/v) resulted in paracellular transport of FITC-dextran 10,000, but morphological changes, i.e. swelling of cells and mucus extrusion, were observed. Conclusions. Confocal laser scanning microscopy is a suitable approach to visualize the transport pathways of high molecular weight hydrophilic compounds across nasal epithelium, and to study the effects of absorption enhancers on drug transport and cell morphology.
引用
收藏
页码:631 / 637
页数:7
相关论文
共 23 条
[1]  
AGERHOLM C, 1994, J PHARM SCI, V83, P618
[2]  
Bacallao Robert, 1995, P311
[3]   THE EFFECT OF SODIUM TAURO-24,25-DIHYDROFUSIDATE ON THE NASAL ABSORPTION OF HUMAN GROWTH-HORMONE IN 3 ANIMAL-MODELS [J].
BALDWIN, PA ;
KLINGBEIL, CK ;
GRIMM, CJ ;
LONGENECKER, JP .
PHARMACEUTICAL RESEARCH, 1990, 7 (05) :547-552
[4]   NASAL ABSORPTION IN RATS .2. EFFECT OF ENHANCERS ON INSULIN ABSORPTION AND NASAL HISTOLOGY [J].
CHANDLER, SG ;
ILLUM, L ;
THOMAS, NW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 76 (1-2) :61-70
[5]   THE EFFECTS OF PERMEATION ENHANCERS ON THE SURFACE-MORPHOLOGY OF THE RAT NASAL-MUCOSA - A SCANNING ELECTRON-MICROSCOPY STUDY [J].
ENNIS, RD ;
BORDEN, L ;
LEE, WA .
PHARMACEUTICAL RESEARCH, 1990, 7 (05) :468-475
[6]   DIIODO-L-TYROSINE-LABELED DEXTRANS AS MOLECULAR-SIZE MARKERS OF NASAL ABSORPTION IN THE RAT [J].
FISHER, AN ;
ILLUM, L ;
DAVIS, SS ;
SCHACHT, EH .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (07) :550-554
[7]   INTRANASAL ESTRADIOL ADMINISTRATION TO OOPHORECTOMIZED WOMEN [J].
HERMENS, WAJJ ;
BELDER, CWJ ;
MERKUS, JMWM ;
HOOYMANS, PM ;
VERHOEF, J ;
MERKUS, FWHM .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1991, 40 (01) :35-41
[8]   THE STRUCTURAL BARRIER OF ABSORPTIVE MUCOSAE - SITE DIFFERENCE OF THE PERMEABILITY OF FLUORESCEIN ISOTHIOCYANATE-LABELED DEXTRAN IN RABBITS [J].
HOSOYA, KI ;
KUBO, H ;
NATSUME, H ;
SUGIBAYASHI, K ;
MORIMOTO, Y ;
YAMASHITA, S .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1993, 14 (08) :685-695
[9]  
HURNI MA, 1993, J PHARMACOL EXP THER, V267, P942
[10]  
JEON SY, 1995, ANN OTO RHINOL LARYN, V104, P895